Axela生物传感器
阶段
Unattributed VC -二世 |活着总了
5.8美元关于Axela生物传感器
Axela交付的使命是提供一个简单而有效的方法来个性化医疗利用dotLab体系在研究市场今天创造明天的诊断。这个策略提供一个共同的技术平台,充分利用两个市场的目标是提供一个机会发现。方法已经导致应用程序地址段的潜力大,服务水平低下的癌症和心脏病学市场的焦点将安装两个今年夏天资助的临床试验和不断增长的客户群。一段时间这些领先的临床研究人员可以利用蛋白质相互作用的直接理解发展定量分析在单一平台。点技术缩短了从蛋白质发现过渡到应用程序。能够实时测量生物分子复合物旨在提供疾病管理的新方法。
缺失:Axela生物传感器的产品演示和案例研究
促进你的产品提供技术买家。
达到1000年代的买家使用CB的见解来确定供应商,演示产品,德赢体育vwin官方网站做出购买决定。
缺失:Axela生物传感器的产品&微分器
不要让你的产品被跳过。买家使用我们的供应商排名名单公司和驱动(rfp)请求建议。
专家集合包含Axela生物传感器
专家集合是analyst-curated列表,突出了公司你需要知道的最重要的技术空间。
Axela生物传感器中2专家集合,包括癌症。
癌症
4784件
制药和生物技术公司与癌症治疗药物的候选人。
生物制药技术
5241件
公司参与研究、开发和商业化的化学或生物衍生& theranostic治疗药物。不包括维生素/补充剂,横/临床试验服务。
Axela生物传感器专利
Axela生物传感器已经提出12项专利。
3最受欢迎的专利主题包括:
- 分析化学
- 集群的区别
- EC 3.4.24
申请日 |
授予日期 |
标题 |
相关的话题 |
状态 |
|---|---|---|---|---|
|
2/22/2018 |
4/19/2022 |
流体动力学、分析化学、流体力学、质谱分析、阀门 |
格兰特 |
申请日 |
2/22/2018 |
|---|---|
授予日期 |
4/19/2022 |
标题 |
|
相关的话题 |
流体动力学、分析化学、流体力学、质谱分析、阀门 |
状态 |
格兰特 |
最新的Axela生物传感器新闻
2018年8月22日
摘要Axela公司Axela,以前Axela生物传感器公司是光学技术解决方案的提供者。公司提供Ziplex系统Flowthru TipChips, panelPlus TipChips,衍射光学技术、衍射光学传感器,panelPlus传感器和软件产品。它提供了技术和应用支持,现场和自身的培训,延长保修,服务和维护合同;和自定义应用程序开发服务。公司和内容创建工具来简化多元生物标志物检测转化研究和诊断测试。市场其产品通过网络经销商在加拿大、爱尔兰、比利时、卢森堡、西班牙、荷兰、英国和美国。Axela总部位于多伦多,安大略省,加拿大。Axela公司医疗设备交易和联盟为您提供全面的数据和趋势分析公司并购的MAs,伙伴关系和融资。报告提供详细信息的并购,股票/债券发行、私募股权、风险融资和合作公司交易记录的一个五年计划。报告提出了详细的比较数据,交易数量和他们的价值分为交易类型,界别分组和地区。 GlobalData derived the data presented in this report from proprietary inhouse Medical eTrack deals database, and primary and secondary research. Scope Financial Deals Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. Deals by Year Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. Deals by Subsector Chart and table showing information on the number of deals and value reported by the company, by subsector. Major Deals Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios. Business Description A brief description of the company's operations. Key Employees A list of the key executives of the company. Important Locations and Subsidiaries A list and contact details of key centers of operation and subsidiaries of the company. Key Competitors A list of the key competitors of the company. Key Recent Developments A brief on recent news about the company. Reasons to Buy Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period. Understand the company's business segments' expansion / divestiture strategy The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy. Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios. Equip yourself with detailed information about the company's operations to identify potential customers and suppliers. The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors. Stay uptodate on the major developments affecting the company Recent developments concerning the company presented in the profile help you track important events. Gain key insights into the company for academic or business research Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs. Note*: Some sections may be missing if data is unavailable for the company. Related Biotechnology, Pharmaceutical and Healthcare News
Axela生物传感器常见问题(FAQ)
Axela生物传感器的总部在哪里?
Axela生物传感器的总部位于50荣森,多伦多。
Axela生物传感器的最新一轮融资是什么?
Axela生物传感器的最新一轮融资是Unattributed VC - II。
Axela生物传感器筹集了多少钱?
Axela生物传感器筹集了总计5.8美元。
Axela生物传感器的投资者是谁?
Axela生物传感器的投资者包括VG伙伴,MMV金融、门槛企业和卡温顿基金。
Axela生物传感器的竞争对手是谁?
Axela生物传感器的竞争对手包括Sesen生物、MolecularMD Amnis公司Inotek制药、地区,Everist健康,Evogen, BioVidria Lipomics技术、卡尺生命科学和15。
竞争对手比较Axela生物传感器
变化有几个研究项目在基础科学领域,将提高我们对癌症的理解过程,包括项目丰富的功能基因组学。他们有长期承诺的发展项目,促进这些基本的翻译科学发现转化为攻击癌症治疗策略,从而改善人类健康。
固相生物科学公司收到STTR二期赠款项目的标题为:药物发现铅优化芯片的发展。他们奖资助在2009年美国复苏与再投资法案和他们的项目将解决饲料复合铅优化芯片的进一步发展和商业化(Multizyme芯片)高通量代铅化合物的类似物加上细胞筛选生物活性的快速识别衍生品。这种能力直接影响药物发现的一个关键瓶颈;即铅化合物的高效优化与最优开发药物药理性质。固相生物科学公司提出把六个生物催化与生物活性化合物的药理筛选提供快速识别特异性的目标,这是一个新的范例铅优化。此外,Multizyme芯片平台将在相关行业,适合领导优化包括农用化学品、化妆品和药妆品。固相技术将因此提高竞争力和效率的制药、化妆品、化学工业,将作为丰富的新的和改进的商业产品。这项研究的广泛影响是固相生物科学的进步将实现向创造更好、更安全的药物,这些药物降低开发成本,提高制药行业的整体效率。固相将生成Multizyme芯片供制药和生物技术公司,以促进他们的购买铅优化程序,特别是那些涉及天然product-derived和复杂的合成小分子线索。低温贮藏技术开发的第二阶段将使芯片的销售和chip-handling设备生产阶段,并将允许固相技术平台的无缝渗透进入该公司的目标市场。 Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.
原名Sceptor,这家公司是一个全球诊断,生物收集和检测系统公司致力于提高生活质量和安全的世界会议的需要多个市场,包括研究、临床、环境和生物诊断。
Chalex集团的组成有房间的麦克马斯特大学研究人员所使用的幻灯片是计数,实验室,nematologists兽医从业人员在世界各地。明确的耐用丙烯酸为长期使用,公司的幻灯片也特性精确量由于射出成型精度产生一致的测试结果比其他幻灯片与手工室间距器。这些幻灯片的质量使其世界各地的标准。
没有人原型喷气式飞机或汽车没有通过一个计算机模型运行经验数据。临床试验也是一个原型。现在,制药公司可以模拟尽可能多的场景需要优化的成功最终设计的临床试验。从Immunetrics nBiosimulation技术公司旨在提供从研究和实验,试验设计的桥梁。Immunetrics”工具旨在提供预测计算机模型基于生物机制。输入病人资料;输出的预测临床标记和临床相关的端点。通过这些数据,Immunetrics创建了一个仿真平台进行虚拟实验,可以帮助制药公司锁定人类研究的设计是成功的优化。nImmunetrics是唯一已知机械建模公司提供临床试验结果的预测,远远超过通过或失败。
ReaMetrix, inc .)是一个美国和印度生物技术公司旨在提供高质量的研究和诊断试验解决方案导致印度的机会成本转变成价值的生物技术和全球卫生部门。ReaMetrix相信印度的资源会带来重要价值识别和解决发展中国家的卫生保健需求,和由此产生的产品往往会带来更多的负担得起的替代产品在发达国家。
发现正确的解决方案为您的团队
CB见解德赢体育vwin官方网站科技市场情报平台分析数百万数据点在供应商、产品、合作关系,专利来帮助您的团队发现他们的下一个技术解决方案。